Maxing Shigan for COVID-19

c19early.org

COVID-19 Treatment Clinical Evidence

COVID-19 involves the interplay of 400+ viral and host proteins and factors, providing many therapeutic targets. c19early analyzes 6,000+ studies for 210+ treatments—over 17 million hours of research. Only three high-profit early treatments are approved in the US. In reality, many treatments reduce risk, with 25 low-cost treatments approved across 163 countries.

Naso/oropharyngeal treatment Effective Treatment directly to the primary source of initial infection.
Healthy lifestyles Protective Exercise, sunlight, a healthy diet, and good sleep all reduce risk.
Immune support Effective Vitamins A, C, D, and zinc show reduced risk, as with other viruses.
Thermotherapy Effective Methods for increasing internal body temperature, enhancing immune system function.
Systemic agents Effective Many systemic agents reduce risk, and may be required when infection progresses.
High-profit systemic agents Conditional Effective, but with greater access and cost barriers.
Monoclonal antibodies Limited Utility Effective but rarely used—high cost, variant dependence, IV/SC admin.
Acetaminophen Harmful Increased risk of severe outcomes and mortality.
Remdesivir Harmful Increased mortality with longer followup. Increased kidney and liver injury, cardiac disorders.

Maxing Shigan may be beneficial for COVID-19 according to the studies below. COVID-19 involves the interplay of 400+ viral and host proteins and factors providing many therapeutic targets. Scientists have proposed 11,000+ potential treatments. c19early.org analyzes 210+ treatments. We have not reviewed Maxing Shigan in detail.

Studies suggesting benefit with Maxing Shigan

Wang et al., Network pharmacology research of mechanism of Maxing Shigan Decoction in treating COVID‐19, Quantitative Biology, doi:10.15302/J-QB-022-0307

BackgroundThe COVID‐19 has a huge negative impact on people’s health. Traditional Chinese Medicine (TCM) has a good effect on viral pneumonia. It is of great practical significance to study its pharmacology.MethodsThe ingredients and targets of each herb in Maxing Shigan Decoction which obtained from Traditional Chinese Medicine Systems Pharmacology (TCMSP) database, and the related targets of COVID‐19 were screened by GeneCards database based on the network pharmacology. Venn was used to analyze the intersection target between active ingredients and diseases. Cytoscape software was used to construct an active ingredient‐disease target network. The Protein‐Protein Interaction network was constructed by STRING database and Cytohubba was used to screen out the key targets. Gene Ontology (GO) functional enrichment analysis and KEGG pathway analysis were performed by David database.ResultsIn this study, a total of 134 active ingredients and 229 related targets, 198 targets of COVID‐19 and 48 common targets of drug‐disease were chosen. Enrichment items and pathways were obtained through GO and KEGG pathway analysis. The predicted active ingredients were quercetin, kaempferol, luteolin, naringenin, glycyrol, and the key targets involved IL6, MAPK3, MAPK8, CASP3, IL10, etc. The results showed that the active ingredients of Maxing Shigan Decoction acted on multiple targets which played roles in the treatment of COVID‐19 by regulating inflammation, immune system and other pathways.ConclusionsThe main contribution of this paper is to use data to mine the principles of the treatment of COVID‐19 from the pharmacology of these prescriptions, and the results can be provided theoretical reference for medical workers.

Ji, X., Network Pharmacology Study of Action Mechanism of Traditional Chinese Medicine in The Treatment Of COVID-19, Highlights in Science, Engineering and Technology, doi:10.54097/5edjj687

Big data was utilized to analyze the network of biological systems and multi-target drug signal nodes, and despite traditional Chinese medicine proving effective against COVID-19 since the 2019 outbreak, the complexity and challenging actions of network pharmacology are essential for in-depth analysis. Objective: To present an overview of the literature on the mechanism of traditional Chinese medicine (TCM) in the treatment of COVID-19 based on network pharmacology. Methods: A succinct explanation of the data sources: Twenty items in all were found after browsing the English and Chinese data websites. Following screening, data synthesis techniques and the remaining eight publications were located. Results: This study contained eight publications, including network pharmacology investigations on the mechanisms of action of eight prescription TCM medications. Many prescription drugs and specialty treatments from traditional Chinese medicine, including astragalus membranaceus-atractylodes rhizoma, LHQW, TJQWG, ephedra and glycyrrhiza, Yinqiao powder, rhizoma polygonati, MXSGD, and HSBDF, have been utilized in the clinical treatment of COVID-19. Their primary modes of action entail several components working on many targets and pathways related to immune modulation, organ protection, antiviral, and anti-inflammatory properties. Conclusion: This study reviewed eight Chinese herbal formulas used for treating COVID-19 and found they all contain quercetin, a compound that may reduce lung damage, and target at least one of TNF, IL-2, or IL-6, potentially decreasing inflammation and boosting immunity. All these traditional Chinese medicine (TCM) treatments were effective against COVID-19, offering valuable insights and inspiration for future drug research.